- Home
- MAIA vs ANVS Comparison
MAIA vs ANVS Comparison
Compare MAIA & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAIA
- ANVS
- Stock Information
- Founded
- MAIA 2018
- ANVS 2008
- Country
- MAIA United States
- ANVS United States
- Employees
- MAIA N/A
- ANVS N/A
- Industry
- MAIA Biotechnology: Pharmaceutical Preparations
- ANVS Biotechnology: Pharmaceutical Preparations
- Sector
- MAIA Health Care
- ANVS Health Care
- Exchange
- MAIA Nasdaq
- ANVS Nasdaq
- Market Cap
- MAIA 56.3M
- ANVS 55.5M
- IPO Year
- MAIA 2022
- ANVS 2020
- Fundamental
- Price
- MAIA $1.70
- ANVS $2.89
- Analyst Decision
- MAIA
- ANVS Strong Buy
- Analyst Count
- MAIA 0
- ANVS 4
- Target Price
- MAIA N/A
- ANVS $18.00
- AVG Volume (30 Days)
- MAIA 468.1K
- ANVS 346.4K
- Earning Date
- MAIA 08-08-2025
- ANVS 08-14-2025
- Dividend Yield
- MAIA N/A
- ANVS N/A
- EPS Growth
- MAIA N/A
- ANVS N/A
- EPS
- MAIA N/A
- ANVS N/A
- Revenue
- MAIA N/A
- ANVS N/A
- Revenue This Year
- MAIA N/A
- ANVS N/A
- Revenue Next Year
- MAIA N/A
- ANVS N/A
- P/E Ratio
- MAIA N/A
- ANVS N/A
- Revenue Growth
- MAIA N/A
- ANVS N/A
- 52 Week Low
- MAIA $1.40
- ANVS $1.11
- 52 Week High
- MAIA $3.74
- ANVS $11.29
- Technical
- Relative Strength Index (RSI)
- MAIA 44.78
- ANVS 58.30
- Support Level
- MAIA $1.64
- ANVS $2.63
- Resistance Level
- MAIA $1.74
- ANVS $2.89
- Average True Range (ATR)
- MAIA 0.09
- ANVS 0.23
- MACD
- MAIA -0.01
- ANVS 0.01
- Stochastic Oscillator
- MAIA 11.76
- ANVS 83.08
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.